Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of CX11 for obesity.

Neuren has confirmed the primary goals for its double-blind, single Phase III pivotal trial of NNZ-2591 in treating PMS for 13 weeks.

A study by Larsen and colleagues has exemplified the role that HCs have in heightening depression risk in this group.

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced solid tumours.